1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 1,128 | 1,244 | 10:24 |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| MOLECURE Aktie jetzt für 0€ handeln | |||||
| 28.03.25 | Strategic update on the progress and development of Molecure's key clinical projects in 2024 | 383 | GlobeNewswire (Europe) | Molecure achieved key milestones in the development of its innovative therapies in 2024 and plans to accelerate research and development in its most advanced clinical programs: OATD-01 and OATD-02.... ► Artikel lesen |
1 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| CO.DON | 0,014 | -22,22 % | EQS-AFR: CO.DON AG i.l.: Vorabbekanntmachung über die Veröffentlichung von Finanzberichten gemäß §§ 114, 115, 117 WpHG | EQS Vorabbekanntmachung Finanzberichte: CO.DON AG i.l.
/ Vorabbekanntmachung über die Veröffentlichung von Rechnungslegungsberichten
CO.DON AG i.l.: Vorabbekanntmachung über die... ► Artikel lesen | |
| SANGAMO THERAPEUTICS | 0,290 | -3,14 % | Sangamo Therapeutics, Inc.: Sangamo Therapeutics Advances Rolling Submission of BLA to U.S. FDA for ST-920 in Fabry Disease | Data support potential of isaralgagene civaparvovec as a one-time, well tolerated and durable Fabry disease gene therapy to provide meaningful, multi-organ clinical benefits that could fundamentally... ► Artikel lesen | |
| IMMATICS | 8,480 | +0,06 % | Immatics Presents IMA203CD8 PRAME Cell Therapy Data from Ongoing Dose Escalation and Shows Promising Initial Anti-tumor Activity in PRAME-Positive Tumors at ESMO-IO 2025 Congress | IMA203CD8 is a second-generation PRAME cell therapy with enhanced pharmacology in ongoing Phase 1a dose escalationManageable tolerability across all dose levelsEncouraging early clinical anti-tumor... ► Artikel lesen | |
| ALDEYRA | 1,584 | -0,47 % | Aldeyra Therapeutics, Inc.: Aldeyra Therapeutics to Participate in the Jefferies Global Healthcare Conference in London | Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed to treat immune-mediated diseases, today announced... ► Artikel lesen | |
| MEDIFAST | 8,318 | -0,48 % | Medifast: OPTAVIA Premieres Second Docuseries Episode "Health by Design: Spain" Exploring Metabolic Health and Longevity | Thousands of Independent Coaches Gather Nationwide to Discuss Solutions to America's Metabolic Health Crisis Medifast (NYSE: MED), the health and wellness company known for its science-backed... ► Artikel lesen | |
| PHARMING | 1,410 | -0,70 % | Pharming Group N.V.: Pharming Group receives positive CHMP opinion for Joenja (leniolisib) for the treatment of APDS in adult and pediatric patients 12 years and older | If approved, Joenja® (leniolisib) would become the first approved treatment in the European Union for activated phosphoinositide 3-kinase delta (PI3Kd) syndrome (APDS), a rare primary immunodeficiencyDecision... ► Artikel lesen | |
| COHERUS ONCOLOGY | 1,431 | -0,42 % | Coherus Oncology, Inc.: Coherus Oncology Reports Full Year and Fourth Quarter 2025 Financial Results and Provides Business Update | - LOQTORZI net revenue more than doubled to $40.8 million in 2025 from $19.1 million in 2024 - - Reduced secured and convertible debt by 90% from $480 million to $38.8 million over 2024-2025 - - $172.1... ► Artikel lesen | |
| ORUKA THERAPEUTICS | 39,000 | -1,02 % | Piper Sandler bestätigt "Overweight"-Rating für Oruka Therapeutics | ||
| INNOVIVA | 19,400 | -1,02 % | Innoviva, Inc. - 10-K/A, Annual Report | ||
| SYNDAX PHARMACEUTICALS | 20,400 | 0,00 % | Jefferies senkt Kursziel für Syndax Pharmaceuticals, bestätigt aber Kaufempfehlung | ||
| ARMATA PHARMACEUTICALS | 8,000 | 0,00 % | Armata Pharmaceuticals, Inc.: Armata Pharmaceuticals Announces Fourth Quarter and Full-Year 2025 Financial Results | LOS ANGELES, March 25, 2026 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a late clinical-stage biotechnology... ► Artikel lesen | |
| LIQUIDIA | 32,160 | +0,69 % | Indivior, Liquidia, Crinetics top Quant pharma list as Merck scoops up Terns for $6.7B | ||
| DBV TECHNOLOGIES | 3,630 | +2,98 % | DBV Technologies S.A.: DBV Technologies Announces Filing of 2025 Annual Report on Form 10-K and Universal Registration Document | Châtillon, France, March 26, 2026
DBV Technologies Announces Filing of 2025 Annual Report on Form 10-K and Universal Registration Document
DBV Technologies (Euronext: DBV - ISIN: FR0010417345... ► Artikel lesen | |
| BRAINSTORM CELL THERAPEUTICS | 0,673 | -100,00 % | BrainStorm Cell Therapeutics Inc.: Brainstorm Cell Therapeutics Secures Second $1 Million Strategic Placement; Total $2 Million Raised In February | NEW YORK, Feb. 26, 2026 /PRNewswire/ -- Brainstorm Cell Therapeutics Inc. (OTCQB: BCLI), a leading developer of adult stem cell therapies for neurodegenerative... ► Artikel lesen | |
| SIGA TECHNOLOGIES | 5,285 | +6,66 % | SIGA Technologies declares $0.60/share |
MOLECURE SA gehört der Branche Biotechnologie an. Der aktuelle Kurs liegt bei 1,182 Euro und damit -1,66 % im Minus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu MOLECURE SA finden Sie auf Wallstreet Online.